Results 131 to 140 of about 20,010 (263)

Endocrine therapy‐induced cancer‐related fatigue in hormone‐dependent malignancies: Mechanisms, impact, and management strategies

Precision Medical Sciences, EarlyView.
Multipathway schematic of endocrine therapy–induced cancer‐related fatigue. Endocrine interventions trigger four interacting mechanisms—neuroendocrine dysregulation, systemic inflammation, energy‐metabolic failure, and psycho‐behavioral amplification—that culminate in the multidimensional CRF phenotype.
Jiajing Jiang, Jun Lu, Sen Qin, Ruzhou Chen, Qiuchen Zhang, Lvqi He, Yubei Li, Jingyao Yan   +7 more
wiley   +1 more source

Androgen Receptor Point Mutations: A Mechanism of Therapeutic Resistance and a Framework for Rational Drug Design. [PDF]

Cancers (Basel)
Colah A, Ferková S, Zhang H, Liu G, MacGillivray L, Boudreault PL, Ricke W.   +6 more
europepmc   +1 more source

Androgen Receptor Antagonist TRC253 [PDF]

, 2020
openaire   +1 more source

One‐year follow‐up after fractionated ultra‐high‐dose‐rate FLASH radiotherapy in patient with extramammary Paget disease of the scrotum

Precision Radiation Oncology, EarlyView.
An elderly male patient with extramammary Paget disease of the scrotum and multiple metastases was treated with fractionated FLASH‐RT (40 Gy in 5 fractions) in the scrotal lesion. Abstract Objective Ultrahigh‐dose‐rate radiotherapy (FLASH‐RT) has been shown to reduce radiation‐induced normal tissue injury in preclinical studies.
Hui Luo, Chengliang Yang, Ronghu Mao, Leijie Ma, Hongchang Lei, Peng Chen, Yanping Zhang, Meng Xu, Chao Wang, Yiwu Wang, Mingxia Wu, Chanjun Sun, Han Liu, Hui Liu, Hong Ge   +14 more
wiley   +1 more source

An Update on the Role of Androgens and Androgen Receptor in Triple-Negative Breast Cancer. [PDF]

Cells
Cortes BC, Queiroga FL, Illera JC, Ramos SC.   +3 more
europepmc   +1 more source

Prognostic Role of Serum Neuron‐Specific Enolase at Baseline and its Early Dynamics in Metastatic Castration‐Resistant Prostate Cancer Treated With Androgen Receptor Signaling Inhibitors

The Prostate, EarlyView.
ABSTRACT Background Outcomes of metastatic castration‐resistant prostate cancer (mCRPC) treated with androgen receptor signaling inhibitors (ARSIs) vary widely and may not be fully reflected by PSA and standard clinicopathologic factors. We evaluated the prognostic value of serum neuron‐specific enolase (NSE) at baseline and early on‐treatment dynamics.
Ondřej Fiala, Michaela Tkadlecová, Zuzana Váchalová, Milan Hora, Jan Králíček, Petr Stránský Jr., Václav Liška, Matteo Santoni, Giuseppe Luigi Banna, Kristýna Pivovarčíková, Ondřej Topolčan, Jindřich Fínek   +11 more
wiley   +1 more source

Precision Targeted Therapy for PCOS: Emerging Drugs, Translational Challenges, and Future Opportunities. [PDF]

Biomedicines
Wu X, Yi W, Liu X.
europepmc   +1 more source

Efficacy, Safety, and Cost‐Effectiveness of Reduced versus Full Initial Doses of Androgen Receptor Signaling Inhibitors in Non‐Metastatic Castration‐Resistant Prostate Cancer: A Multicenter Retrospective Study

The Prostate, EarlyView.
ABSTRACT Background The introduction of novel androgen receptor signaling inhibitors (ARSIs) has substantially transformed the systemic treatment landscape for non‐metastatic castration‐resistant prostate cancer (nmCRPC). Unfortunately, ARSI therapy is associated with considerable adverse events (AEs) and high medical costs.
Himawari Asanuma, Naoki Fujita, Shumon Kato, Yohei Kawashima, Masanao Shinohara, Ryuji Tabata, Fumiya Yoneyama, Ryuma Tanaka, Takuya Oishi, Hikari Miura, Kyo Togashi, Kazutaka Okita, Hirotaka Horiguchi, Toshikazu Tanaka, Daisuke Noro, Yuichiro Suzuki, Satoshi Sato, Chikara Ohyama, Shingo Hatakeyama   +18 more
wiley   +1 more source

Intratumoral Androgens and Genetic Variants Driving Therapy Resistance in Prostate Cancer. [PDF]

Research (Wash D C)
Ye J, Xie Y, Wang J, Wu R, Li D, Yoo KH, Wusiman D, Cho WC, Lyu Z, Feng D.   +9 more
europepmc   +1 more source

Mapping the Radiopharmaceutical Therapy Landscape for Prostate Cancer: Insights Into Global Clinical Trial Trends and Future Directions

Med Research, EarlyView.
Zhiwu Dong, Sixiang Yan, Xiaodong Liu, Peng Gu   +3 more
wiley   +1 more source